Effect of Esketamine combined with transversus abdominis muscle block on postoperative pain in patients undergoing laparoscopic radical colorectal cancer surgery: a randomized controlled trial

Application of Esketamine combined with transversus abdominis muscle plane block in radical operation of colorectal cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070679

Enrollment

Unknown

Registered

2023-04-20

Start date

2023-04-20

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

laparoscopic radical colorectal cancer surgery

Interventions

Group C:general anesthesia

Group T:General anesthesia and transversus abdominis muscle block

Group E:General anesthesia and Esketamine

Group TE:General anesthesia,transversus abdominis muscle block and Esketamine

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Patients who plan to undergo laparoscopic radical resection of colorectal cancer under general anesthesia, aged 18-85 years, regardless of gender; (2) ASA Level I-III, Mallampati Level I-II; (3) Received postoperative patient controlled intravenous analgesia (PCIA) treatment; (4) No serious lesions in important organs such as the heart, lungs, and brain, and no significant abnormalities in liver and kidney function; (5) voluntarily participate in clinical trial, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Allergies to the drugs required for use in this study; (2) Presence of infection at the puncture site; (3) Individuals with abnormal heart, liver, and kidney functions; Blood pressure = 180/100 mmHg; Untreated or poorly controlled hypertension; (4) Individuals with mental illness who are unable to cooperate; Preoperative inability to communicate due to cognitive or language impairment; (5) Other situations where the researcher determines that the patient is not suitable to participate in the clinical trial.

Design outcomes

Primary

Measure	Time frame
Pain Visual Analogue Scale;Quality of postoperative recovery;	—

Secondary

Measure	Time frame
PCIA usage: dosage of sufentanil, effective pressing times of PCIA, times of remedial analgesia;Operation time, anesthesia time;dosage of remifentanil and propofol during operation;awakening time, exhaust time,awakening time;PACU time, and hospital stay;untoward effect;	—

Countries

China

Contacts

Public ContactZhiguo Tao

Department of Anesthesiology, Chaohu Hospital Affiliated to Anhui Medical University

zhgtau@163.com+86 13625651122

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026